REG-GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Gilead Sciences and Lakefront Biotherapeutics completed the $1.675 million acquisition of Ouro Medicines to secure gamgertamig, a clinical-stage T cell engager for autoimmune diseases. Gamgertamig has received Fast Track and Orphan Drug Designation for AIHA and ITP, with registrational studies expected to begin as early as 2027.
Key figures
- Deal Value Usd
- $1,675 million
- Royalty rate
- 20%–23%
- Opt in cost per program
- $75 million
- Lakefront buyback capacity
- $150 million
- Contingent milestone payments
- $500 million
- Expected 2026 cash balance lakefront
- €2B
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.